Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Modafinil
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Apotex Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Apotex Acquires US rights to PROVIGIL® (modafinil) and NUVIGIL® (armodafinil)
Details : Acquiring the US rights to PROVIGIL (modafinil) and NUVIGIL (armodafinil) indicated to improve wakefulness in adult patients marks a strategic milestone for Apotex.
Product Name : Provigil
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 09, 2025
Lead Product(s) : Modafinil
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Apotex Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Modafinil
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Acquisition
Neuraxpharm Acquires Provigil®, Nuvigil® to Expand Branded Business
Details : Neuraxpharm has acquired these products Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of EDS in adults with narcolepsy.
Product Name : Provigil
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 07, 2025
Lead Product(s) : Modafinil
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Modafinil
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Chemipharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Modafinil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 11, 2023
Lead Product(s) : Modafinil
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Chemipharm
Deal Size : Inapplicable
Deal Type : Inapplicable